Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm pretty sure it went from .66 to 1.08 in the past weeks. So yes it goes up.
The traders will have this pegged based on charts and the lemmings will make this go up and go down as they all follow each other.
Partnership or unbelievable results that hit national news wires will skip that beat and take us to new highs. Imo
Here s what I know; the data was great. Especially when you correlate the preclinical data and images to the facts on safety of Ziagen combined with phase 2a at 200 mg dose. IPIX is just finding the sweet spot and doing it in a professional way. 400mg could provide AMAZING results. Imo
Excellent Post!!!
Leo can't release PR's as he sits across the table with a team of Pfizer Execs. Lol. Now can he?
Eyes on the prize! It's almost "unbelievable" the success that IPIX is having in trials. Possibly that is our problem ;$)
I think we have a big week. I'm always hopeful that blockbuster PR drops.
I'm going to get an email out to some of my crew today. I'll post it here later in the day. I may start pushing the envelope too now and really promoting this to my extended circle. I've been hesitant and now feel the risk here has been extremely cut in half or more with yesterday's results.
Let's have a great day
Yes. Exactly. I'm not a doctor nor have ever had enemas so I can't say for sure. What I do know, is that this B-UP trial was thrown together very quickly after IPIX met at conference in Florida not to long ago and signed industry leaders to give their opinion on the path they have just taken.
It was overwhelmingly suggested to move forward with this trial. IPIX did not have the time or resources to gamble on for formulation. This was simply a PROOF OF CONCEPT trial, and if the results were good...it would leads to formulation for optimization. We are at that point now. As you can read in yesterday's PR.
This trial literally was brilacidin combined with water. A gel or foam imo will coat and stick to the walls much better imo.
A partner is imminent. IMO. This data yet very small is extremely promising.
Worth a READ! Thx Sox
Formulation to optimize B will take this into the 70 - 80's and beyond possibly. I can't wait. The FDA is going to love this data. IMO.
Proof in a picture! Thanks
Only message boards could spin today and cast doubt. This was an amazing presentation that will speak loudly to BP. I can guarantee this put a little more pressure behind some of the CDAs
Great slideshow and the 67% remission rate was amazing not to mention the images.
I'm going to celebrate!!!!
Congrats all longs and future IPIX holders.
Congrats IPIX on staying perfect 5 for 5 in human clinical trials.
That is no small feat
Thank you for that!!! agree
Okay. Have not looked at slides
I do enough research on this and I'm blown away. But I need confirmation.
Sox or all Docs. Like I'm freaking out...that is amazing data....right? Please someone confirm that is better than industry leading drugs!!!! And we combined with water!!!! Foam and gel still to come
Wow
Closing bell!!! Let's see how cohort c did!!!
Wow. Keep up the great info!!! Very good DD and comparisons.
Awesome! Thank you! Today will hopefully be great. Data wise!!!! I care less about share price obviously, I'd like to keep adding my 2-500 shares a week at 1.00 rather than 5.00-7.00-9.00 etc...
Endoscopy subscore of ≤ 1 met in 7 of 11 patients (1 patient declined final endoscopy).
PGA subscore improved for 10 of 12 patients.
Rectal Bleeding subscore improved for all 12 patients.
Stool Frequency subscore demonstrated improvement by study end for all patients who were abnormal at study start
------------
That is all we really need to know. That data can help everyone understand the trial. Endoscopic images are the real deal. You can't fake and a picture/video is worth a billion words. Many billion. Only the strong present that in a poc.
Maybe I'm wrong. But tonight...I'm right.
Sleep well children.
Innovation Pharmaceuticals Inc.
July 9, 2017
Ulcerative Proctitis / Ulcerative Proctosigmoiditis — Opportunity for Newer Therapies Like Brilacidin to Emerge
Brilacidin
Ulcerative Proctitis/Ulcerative Proctosigmoiditis
Ulcerative Proctitis and Ulcerative Proctosigmoiditis (UP/UPS) are two mild forms of Ulcerative Colitis (UC), an Inflammatory Bowel Disease (pdf) (IBD), involving only the rectum and distal colon.
UP/UPS can be characterized by inflammation, redness, and ulcerations of the mucosal lining. Symptoms include frequent stools and diarrhea (with or without blood), as well as abdominal urgency, such as cramping and constipation. The clinical course of the disease is highly variable, ranging from complete resolution, to maintained remission, to chronic relapses and refractory disease. Progression of UP/UPS into more extensive disease, to full UC, occurs in up to 50 percent of patients.
The cause of UP/UPS is undetermined, though evidence suggests complex interactions between the environment, the intestinal microbiome, immune dysregulation, and a genetic predisposition, may be contributing factors. Diagnosis can occur at any point in one’s life and there currently is no cure.
According to estimates provided by GlobalData, the Worldwide UC market, which includes UP/UPS, is expected to increase at a compound annual growth rate of 4.7 percent, from $4.2 billion in 2012 to approximately $6.6 billion by 2022. The larger anti-inflammatory market, comprising IBD, arthritis, respiratory disease, multiple sclerosis, psoriasis, and other inflammatory diseases, is expected to reach $106.1 billion by 2020.
Current UP/UPS Treatment Options
IBD therapy generally focuses on anti-inflammatory immunosuppression based on the severity and location of the disease. Rectally-applied treatments can be particularly effective in treating distal colitis -- e.g., suppositories for UP or enema/foam preparations for UPS. Common medications for the treatment of UP/UPS include steroids and 5-aminosalicyclic acid (5-ASA), a $1.4 billion market.
Topical steroids may be administered to patients who fail or do not tolerate 5-ASA therapy. Oral corticosteroids may also be given to patients, though their extended use can be associated with serious side-effects. Rectally-applied steroids offer advantages compared to oral drugs, providing targeted treatment (localized concentration of medication) to areas of active inflammation with less risk of adverse systemic effects.
Budesonide (marketed under the brand name Uceris) is a second-generation corticosteroid used either topically or orally in patients with more limited forms of UC. Both enema and foam formulations are available to treat patients. A six-week course of budesonide foam is recommended to help induce remission, with twice-daily dosing for the first 2 weeks, followed by once-a-day dosing for the remaining 4 weeks. The cost of budesonide foam, around $1,280 for a six-week course, makes it an attractive treatment option compared to more expensive biologic therapies, typically reserved for severe cases of UC. Uceris's patent is set to expire in 2020.
Budesonide was approved by the Food and Drug Administration (FDA) in October 2014 based on two successful Phase 3 trials (published findings) -- 38.3 percent and 44 percent of patients on budesonide foam achieved remission at 6 weeks compared to 25.8 percent and 22.4 percent on placebo. Combined results showed a remission rate of 41.2 percent with budesonide foam and 24 percent with placebo.
In March 2017, Salix Pharmaceuticals, acquired by Valeant Pharmaceuticals for $14.5 billion in 2015, published results showing extended release tablets of budesonide achieved both clinical and endoscopic remission, touting its ability to deliver "complete UC relief" in mild-to-moderate cases, and emphasizing the use of, in its clinical trials, "the stringent endpoint of endoscopic remission." In two trials, 17.9 percent and 17.4 percent of patients taking Uceris tablets achieved remission compared to 7.4 percent and 4.5 percent, respectively, on placebo.
Brilacidin as a Promising, Non-Corticosteriod, Non-Biologic Treatment for IBD
With its unique immunomodulatory profile as a defensin-mimetic -- defensins play a special role in the regulation of mucosa and the intestinal barrier -- Brilacidin is being developed as a promising, novel, non-corticosteroid, non-biologic treatment for IBD.
Innovation Pharmaceuticals completed treatments in the final cohort in its Phase 2 Proof-of-Concept (PoC) clinical trial in UP/UPS and will be presenting topline results at the Drug Discovery & Therapy World Congress in Boston, MA, on July 13, 2017.
Formulation development plans for Brilacidin in IBD include foam and/or gel for the treatment of UP/UPS, as well as tablets for oral dosing in UC and Crohn’s Disease. Newer formulations may result in added retention and a more uniform distribution of Brilacidin, potentially increasing efficacy, while being more amenable to patients.
How come there was no dose escalation in the OM trial? It's either placebo or 3mg/mL B in water.
I'd figure maybe a little more B might be better?
Real Life Possibility: I can see something like this scenario having occurred.
Pfizer: Hello IPIX, I love the possible MOA of Kevetrin. Do you mind if we sign a CDA and watch closely as you go thru your phase 1 trial at Dana Farber?
IPIX: Sure, we would be delighted and honored for you to take a closer look!
Years pass during the Phase 1:
Pfizer: Wow, what fascinating data and possibilities, especially with the disappearance of those tumors in that Ovarian Cancer patient. We feel the need for you to prove the MOA however and we need an even closer look at what effects Kevetrin has on the tumor itself and need some biopsies. Please rearrange your trial design to these conditions... xYZ
IPIX: Sure we are up for the challenge and believe in Kevetrin.
Pfizer: Wow, Brilacidin looks extremely powerful, can we sign a CDA for that as well?
IPIX: Absolutely! We have 3 other Big Pharm on CDA as well for Brilacidin, but please come take a look!
Pfizer: Internal meeting: Wholly "SHI!" team, this Kevetrin and Brilacidin could be blockbusters and not only for one indication, multiple!!! IPIX keeps turning in promising data, set after set! This might get very expensive if we wait around much longer, lets try and get this done with an initial offer: Hi IPIX, we are willing to buy your company for 6 Billion dollars. Take it or leave it.
IPIX: Oh my! That is a great offer and we are honored! However, we have not even come close to the realization of the FULL potential of Kevetrin or Brilacidin yet. Not to mention we are going full speed ahead with an Oral Psoriasis drug that could compete with Biologics. That 6 Billion is just not what we are looking for as an end goal. We have much more to do to maximize our value. But thank you!
Pfizer: Crap!
As time passes - more and more CDA's are signed and more interest and meetings have taken place.
Pfizer: Internal Meeting: Team - we need to make decision on how we want to attack this. This company could have 3 drugs alone that could bring in over 20 billion a year when all said and done...possibly much more! Should we step up or lose our opportunity?
IPIX: Leo and Dr. M and Dr. B, all working hard - day in and day out. Drowning out the noise and simply getting it done. Trial after Trial. Waiting for that offer that they cannot resist.
LOL - I am just saying. There is alot going on behind the scenes. And one day we WILL wake up to something that is more than amazing IMO.
Thursday - I hope for 4 out 5 FULL remission.
Good luck!
Thanks Sox!
Do you think IPIX is at the conference all week?
He has delivered on every occasion if I am not mistaken. Every one of the trials IPIX has ever started have completed "SUCCESSFULLY" so you ask when has he delivered. He has not failed.
Share price is often not associated with actual value for pre-rev biotech. It will recalculate the day there is cash in the bank and we are on a higher exchange will real coverage and large %'s of the float locked up. This is pre-party stage.
Because the 3rd party verification has not occurred yet. 3rd party verification meaning PARTNER/COLLABORATION. This is controlled by charting short term players collecting milk money on every .10 -.30 run. The big show will happen with cash in the bank and an uplist to allow BIG INSTITUTIONAL buyers to suck up 50-80% of the float and keep it stable. For the time being we just sit at whatever price she shows us.
Every day we get closer :)
These are sick numbers! Sick meaning AWESOME! Compared to current available options I am HOPING B sets the world on FIRE for IBD.
This is a "HOT" sector as Leo has mentioned.
I am hoping for some new OM numbers but won't hold my breathe.
B-UP Interim Data Here:
http://www.ipharminc.com/press-release/2017/3/19/cellceutix-releases-favorable-topline-findings-as-part-of-interim-analysis-of-phase-2-drug-candidate-brilacidin-for-the-treatment-of-inflammatory-bowel-disease
Patient Quality of Life (as assessed by the Short Inflammatory Bowel Disease Questionnaire, SIBDQ)—notable improvements in all 12 patients; 50 percent of patients in Cohort A (3 of 6) and 80 percent of patients in Cohort B (5 of 6) reported significant improvements of 15 points to more than 50 points higher on the 70-point SIBDQ scale.
Big GREEN Day here! IPIX.
You will be able to buy more on way up. Everyone will. That is the best part of IPIX. They have so much value and the sp will catch up and reevaluate over the next years.
You may only be able to buy in the teens or higher, once verification occurs via partnership, but ride that into the triple digits as the science continues to dominate. IMO.
Exciting times ahead. I'm feeling we see a P trial full enrollment PR next week.
I'm also hoping for a Kevetrin cohort 1 complete this month.
In regards to Thursday. All of us have a good idea of what to expect from the data. Images or video may be a bonus but the overall scientific community will hopefully enjoy and take notice. Especially if we stick with 50% rates
Fantastic! Thx. We ask for current treatments and remission rates and we get it. Thx Leo.
More like Prurisol data is already in the hands of all CDA holders. There will be a bid much higher than the rest. Trigger finger ready. #KABOOOOOM time. Imo
Sounds interesting. I still believe Kevetrin will be the holy grail.
And then IF there is a deal announced after hours for 8.7 billion. It will open at 54.37 tomorrow. It's really simple.
Can you please provide a link to their doings? Everything I see in the K seems legal? Explain please
That is only your opinion. I am not here to start a pissing match with anyone. I just would appreciate facts. Or state it's your opinion.
I believe David and feel he has put his own company and hard work behind this so to me that is a good sign. He would not throw in 49% of his reputable govt contracted company for a pos tech company. I'd expect imo a big contract for SMS in the healthcare or transportation industry.
Good luck. I'm still questioning your position here? Can you add insight?
Thank you. I am invested in that company example. It's been quite the ride. Biotech is not for the weak, that is for sure.
I hope we hear something in July for K. That would give us a good shot at completing the trial by December.
Maybe we even get something really juicy about cohort 1.
Thanks again.
Everything matters when someone is invested in a company. 100000 shares matter imo. For flippers or day traders it probably does not. But I like the sector, I like the SMS marketing and technology. I work for a small 120 million dollar marketing company. We only market via email and direct mail. There are many companies that have not moved to SMS yet. So imo. This is right where you want to be.
A couple contracts for 40-80 million texts a month and this becomes a million dollar a month revenue generating pig. It's not hard to see.
That is my opinion.